Price cap fallout: Abbott to withdraw two of its coronary stents from India 

The company said it was disappointed that the government has not fixed prices of old and new technology of stents separately Heart of the matter: 5 things to know about pricing of stents The NPPA's decision has caused a fair deal of heartburn to stent makers. Many have threatened to pull out their products from Indian market, while some said that the decision will be detrimental for bringing in innovative therapies to the country. MNCs including Abbott, Medtronics, Meril Lifesciences and Boston Scientific have around 60 percent market share of India’s stent market which is valued at around USD 531 million in revenues by 2016-end. 

The NPPA's move was also intended to put an end to profiteering by stent manufacturers, distributors, hospitals and doctors through highly inflated margins. NPPA study found out that distributors had trade margins between 13 and 196 percent for sale of stents to hospitals, while hospitals enjoyed a margin between 11 percent and 650 percent on sales to patients. Around 25 percent of deaths in India are attributed to cardiovascular disease (CVD). Coronary artery disease (CAD) is the most common CVD accounting for 90-95 percent of all CVD cases and deaths 

 Read more for Best Stock Tips- http://bit.ly/ace_services